ClinicalTrials.gg
CompletedNCT02134028Updated Mar 28, 2022Results posted

Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)

A Phase 3 interventional study of Dupilumab in Asthma, sponsored by Sanofi. Completed at 365 sites in 27 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2022-03-28.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,282
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.

Enrollment
Largest of 31
2,282 · median 120
Started
2014
the only one that year
Phase 3
11 of 31
2 open now
Registered
3rd of 31
by date
Lead sponsor
15 of 31
Sanofi

Among the 31 studies testing dupilumab in Asthma, this one has the largest enrollment, is the only one that started in 2014, is one of 11 in phase 3, and was the 3rd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing dupilumab in Asthma, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the long-term safety and tolerability of dupilumab in participants with asthma who participated in a previous dupilumab asthma study (DRI12544, PDY14192, EFC13579, EFC13691).

Secondary Objectives:

To evaluate the long-term efficacy of dupilumab in participants with asthma who participated in a previous dupilumab asthma clinical study.

To evaluate dupilumab in participants with asthma who participated in a previous dupilumab asthma clinical study, with regards to:

  • Systemic exposure
  • Anti-drug antibodies
  • Biomarkers
Read the detailed description

A screening period, up to 3 weeks, applied only for participants who came from DRI12544 study. The total study duration, per participant, was a maximum of 108 weeks (or 111 weeks considering a maximum screening period of 3 weeks for study DRI12544) for the participants enrolled prior to Amendment 04 approval and a maximum of 60 weeks for the participants enrolled after Amendment 04 approval.

Following amendment 04 (dated 31 Oct 2016) the open-label treatment duration was amended to 48 weeks (1 year); and the 16-week post-treatment period was shortened to 12 weeks.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with asthma who completed the treatment period in a previous dupilumab asthma clinical study (i.e., PDY14192, EFC13579 or EFC13691) or participants with asthma who completed the treatment and follow-up periods in previous dupilumab asthma Study DRI12544.

Exclusion criteria

Exclusion criteria:

  • Participants who experienced any reactions to Medicinal Product (IMP) in the previous dupilumab asthma study, which, in the opinion of the Investigator, could indicate that continued treatment with dupilumab, may present an unreasonable risk for the participant.

The above information was not intended to contain all considerations relevant to a Participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,282 participants (actual)

Study arms

  • Experimental
    dupilumab treatment

    For participants coming from the DRI12544 study: dupilumab loading dose subcutaneous (SC) on Day 1, followed by 1\* Dose every 2 weeks added to current controller medications. For participants coming from other studies: dupilumab 1 \* Dose SC every 2 weeks added to current controller medications.

    Drug: Dupilumab

Interventions

  • Pharmaceutical form: Solution for injection Routes of administration: Subcutaneous

    Also known as: SAR231893, REGN668

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An Adverse Event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily had to have causal relationship with treatment. TEAEs were defined as AEs that developed, worsened, or became serious during the treatment emergent AE period (time from first dose of investigational medicinal product \[IMP\] in LTS12551 up to the last dose of dupilumab plus 14 weeks). A Serious AE (SAE) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.

    Time frame: From the first IMP injection in LTS12551 to the last IMP injection plus 14 weeks (up to 108 weeks)

Secondary outcomes

  1. Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities During the TEAE Period

    Criteria for potentially clinically significant vital sign abnormalities: * Systolic blood pressure (SBP): Less than or equal to (≤) 95 Adults (≤90 Adolescents) millimeters of mercury (mmHg) and decrease from baseline (DFB) greater than or equal to (≥) 20 mmHg; ≥ 160 Adults (≥ 119 Adolescents) mmHg and increase from baseline (IFB) ≥ 20 mmHg. * Diastolic blood pressure (DBP): ≤ 45 Adults (≤54 Adolescents) mmHg and DFB ≥ 10 mmHg; ≥ 110 Adults (≥78 Adolescents) mmHg and IFB ≥ 10 mmHg. * Heart rate (HR): ≤ 50 beats per minute (bpm) and DFB ≥ 20 bpm; ≥ 120 bpm and IFB ≥ 20 bpm. * Respiratory rate: less than (\<) 12 breaths/min(b/m); greater than (\>) 20 b/m. * Weight (kg): ≥ 5 percent (%) DFB; ≥ 5% IFB. * Temperature: ≥ 38.0 degree Celsius (°C) rectal/ear/temporal; ≥ 37.5°C oral; ≥ 37.2°C axillary. TEAE period was defined as the time from first dose of IMP in LTS12551 up to the last dose of dupilumab plus 14 weeks.

    Time frame: From the first IMP injection in LTS12551 to the last IMP injection plus 14 weeks (up to 108 weeks)

  2. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters (Red Blood Cells [RBCs], Platelets and Coagulation) During the TEAE Period

    Criteria for potentially clinically significant abnormalities: * Hemoglobin (Hb): ≤ 115 grams per liter (g/L)(Male \[M\]), ≤ 95 g/L (Female\[ F\]) (\< 100 g/L Adolescents); ≥ 185 g/L (M), ≥ 165 g/L (F) (≥ 200 g/L Adolescents); DFB ≥ 20 g/L. * Hematocrit: ≤ 0.37 volume/volume (v/v) (M); ≤ 0.32 v/v (F) (\<0.32 v/v Adolescents); ≥ 0.55 v/v (M); 0.5 v/v (F) (\>0.47 v/v Adolescents). * RBCs: ≥ 6 Tera/L. * Platelets: \< 100 Giga(G)/L; ≥ 700 G/L. TEAE period was defined as the time from first dose of IMP in LTS12551 up to the last dose of dupilumab plus 14 weeks.

    Time frame: From the first IMP injection in LTS12551 to the last IMP injection plus 14 weeks (up to 108 weeks)

  3. Number of Severe Exacerbation Events

    Severe asthma exacerbation events were defined as a deterioration of asthma which required: use of systemic corticosteroids for ≥ 3 days, (participants from study EFC13691 (NCT02528214), and who were taking systemic corticosteroids: the use of systemic corticosteroids at least double the current dose and for ≥3 days.) or, hospitalization or emergency room visit because of asthma, required systemic corticosteroids.

    Time frame: From the first IMP injection in LTS12551 to the last IMP injection plus 2 weeks (up to 96 weeks)

  4. Annualized Event Rate Per Participant-Years for Severe Exacerbation

    The annualized event rate per participant-years was defined as the total number of events that occurred during the treatment period divided by the total number of participant-years during the treatment period.

    Time frame: From the first IMP injection in LTS12551 to the last IMP injection plus 2 weeks (up to 96 weeks)

  5. Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Weeks 48 and 96

    FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. For this analysis, baseline was defined as respective parent study baseline.

    Time frame: Baseline of parent study, Week 48 and Week 96 of this extension study

  6. Change From Baseline in Percent Predicted FEV1 at Weeks 48 and 96

    FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. For this analysis, baseline was defined as respective parent study baseline.

    Time frame: Baseline of parent study, Week 48 and Week 96 of this extension study

  7. Change From Baseline in Forced Vital Capacity (FVC) at Weeks 48 and 96

    FVC was a standard pulmonary function test used to quantify respiratory muscle weakness. FVC was the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. For this analysis, baseline was defined as respective parent study baseline.

    Time frame: Baseline of parent study, Week 48, and Week 96 of this extension study

  8. Change From Baseline in Forced Expiratory Flow (FEF) 25-75% at Weeks 48 and 96

    FEF was the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF 25-75% was defined as the mean FEF between 25% and 75% of the FVC, where FVC was defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. For this analysis, baseline was defined as respective parent study baseline.

    Time frame: Baseline of parent study, Week 48, and Week 96 of this extension study

  9. Change From Baseline in Asthma Control Questionnaire 5-Question Version (ACQ-5) Mean Scores at Weeks 24 and 48

    The ACQ-5 had 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total mean score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), higher scores indicated lower asthma control. For this analysis, baseline was defined as respective parent study baseline.

    Time frame: Baseline of parent study, Weeks 24, and 48 of this extension study

  10. Percentage of Participants Achieving ACQ-5 Score Response (ACQ-5 Responders) at Weeks 24 and 48

    ACQ-5 response was defined as change from baseline in ACQ-5 scores ≥ 0.5. The ACQ-5 had 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 mean total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.

    Time frame: At Weeks 24, and 48 of this extension study

  11. Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Global Scores at Weeks 24 and 48

    The AQLQ was designed to measure the functional impairments that are most troublesome to adults as a result of their asthma. The AQLQ comprised of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), and environmental stimuli (4 items). Each item was scored on a 7-point likert scale ranged from 1=severely impaired to 7=not impaired. The 32 items of the questionnaire were averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired); higher scores indicated better quality of life. For this analysis, baseline was defined as respective parent study baseline.

    Time frame: Baseline of parent study, Weeks 24, and 48 of this extension study

  12. Percentage of Participants Achieving AQLQ Global Score Response (AQLQ Responders) at Weeks 24 and 48

    AQLQ global response was defined as participants with change from baseline in AQLQ global score ≥ 0.5. The AQLQ was designed to measure the functional impairments that are most troublesome to adults as a result of their asthma. The AQLQ comprised of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item was scored on a 7-point likert scale (1=severely impaired, 7=not impaired). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired). Higher scores indicated better quality of life.

    Time frame: At Weeks 24, and 48 of this extension study

  13. Serum Concentrations of Dupilumab Over Time Till Week 96

    For this analysis, baseline was defined as respective parent study baseline. Here, 'number analyzed'=number of participants with available data for each specified category.

    Time frame: Baseline of parent study, Weeks 0, 4, 12, 24, 48, 72, and 96 of this extension study

  14. Percentage of Participants With Antidrug Antibodies (ADA) Response

    ADA response were categorized as: treatment emergent and treatment boosted response. 1) Treatment emergent was defined as an ADA positive response in the assay post first dose in LTS12551, when baseline results were negative or missing. 2) Treatment boosted was defined as: an ADA positive response in the assay post first dose that was greater-than or equal to 4-fold over baseline titer levels, when baseline results were positive. The criteria for positive was defined as "30 to \> 10,000", where low titer (\< 1,000); moderate (1,000 ≤ titer ≤ 10,000) and high titer (\> 10,000).

    Time frame: From the first IMP injection in LTS12551 to the last IMP injection plus 2 weeks (up to 96 weeks)

  15. Change From Baseline in Blood Eosinophils Cells Count at Weeks 48 and 96

    For this analysis, baseline was defined as respective parent study baseline.

    Time frame: Baseline of parent study, Week 48 and Week 96 of this extension study

  16. Change From Baseline in Morning Peak Expiratory Flow (PEF) at Weeks 48 and 96: Participants From Study DRI12544

    The PEF was a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at morning and evening. Morning PEF was performed within 15 minutes after arising (between 5:30 AM and 10 AM) prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol. For this analysis, baseline was defined as parent study DRI12544 baseline.

    Time frame: Baseline of parent study, Week 48 and Week 96 of this extension study

  17. Change From Baseline in Evening Peak Expiratory Flow (PEF) at Weeks 48 and 96: Participants From Study DRI12544

    The PEF was a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at morning and evening. Evening PEF was performed in the evening (between 5:30 PM and 10 PM) prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol. For this analysis, baseline was defined as parent DRI12544 study baseline.

    Time frame: Baseline of parent study, Week 48 and Week 96 of this extension study

  18. Change From Baseline in Morning Asthma Symptom Scores at Weeks 48 and 96: Participants From Study DRI12544

    Morning asthma symptom score was determined using AM (ante meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the night. It ranges from 0 to 4 as: 0=no asthma symptoms, slept through the night, 1=slept well, but some complaints in the morning. No nighttime awakenings, 2=woke up once because of asthma (including early awakening), 3=woke up several times because of asthma (including early awakening), 4=bad night, awake most of the night because of asthma; higher scores indicated more severe symptoms. For this analysis, baseline was defined as parent DRI12544 study baseline.

    Time frame: Baseline of parent study, Week 48 and Week 96 of this extension study

  19. Change From Baseline in Evening Asthma Symptom Scores at Weeks 48 and 96: Participants From Study DRI12544

    Evening asthma symptom score was determined using PM (post meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual; higher scores indicated more severe symptoms. For this analysis, baseline was defined as parent DRI12544 study baseline.

    Time frame: Baseline of parent study, Week 48, and Week 96 of this extension study

  20. Change From Baseline in Number of Inhalations Per Day of Salbutamol/Albuterol or Levosalbutamol/Levalbuterol for Symptom Relief at Weeks 48 and 96: Participants From Study DRI12544

    The number of salbutamol/albuterol or levosalbutamol/levalbuterol inhalations was recorded daily by the participants in an electronic diary/PEF meter. Mean number of inhalations in last 7 days prior to each visit was calculated and was used in computation of data reported. For this analysis, baseline was defined as parent DRI12544 study baseline.

    Time frame: Baseline of parent study, Week 48, and Week 96 of this extension study

  21. Change From Baseline in Number of Nocturnal Awakenings at Weeks 48 and 96: Participants From Study DRI12544

    The number of nocturnal awakening because of asthma symptoms were recorded every morning by the participants in an electronic diary. Mean number of awakenings in last 7 days prior to each visit was calculated and was used in computation of data reported. For this analysis, baseline was defined as parent DRI12544 study baseline.

    Time frame: Baseline of parent study, Week 48 and Week 96 of this extension study

  22. Percent Change From Baseline in Oral Corticosteroid (OCS) Dose at Weeks 48, and 96: Participants From Study EFC13691

    OCS was allowed as background controller medication for the participants from study EFC13691 only. For this analysis, baseline was defined as parent study EFC13691 baseline.

    Time frame: Baseline of parent study, Weeks 48 and 96 of this extension study

  23. Percentage of Participants Achieving a Reduction of 50% or Greater (≥ 50% ) in OCS Dose Over Time at Weeks 48 and 96: Participants From Study EFC13691

    OCS was allowed as background controller medication for the participants from study EFC13691 only. Percentage of participants who achieved a reduction of ≥ 50% in OCS dose were reported.

    Time frame: Weeks 48 and 96 of this extension study

  24. Percentage of Participants With Background OCS Completely Tapered Off Over Time at Weeks 48 and 96: Participants From Study EFC13691

    OCS was allowed as background controller medication for the participants from study EFC13691 only. Number of participants who gradually discontinued or reduced therapeutic dose were reported in this outcome measure.

    Time frame: Weeks 48, and 96 of this extension study

  25. Change From Baseline in European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Scores at Weeks 48 and 96: Participants From Study DRI12544

    EQ-5D-3L: validated and reliable self-report health status questionnaire consisted of EQ-5D descriptive system and visual analogue scale (VAS). EQ-5D descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension measured on 3 levels: no problem, some problems, and severe problems. The 5 dimensional 3-level systems was converted into single index utility score, and the score was 0 - 100, where 100=best health state; and 0=worst health state; where higher scores indicated better outcome. For this analysis, baseline was defined as parent DRI12544 study baseline.

    Time frame: Baseline of parent study, Week 48 and Week 96 of this extension study

  26. Change From Baseline in EQ-5D-3L VAS Scores at Weeks 48 and 96: Participants From Study DRI12544

    EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0=worst imaginable health state and 100=best imaginable health state, where higher states indicated better outcomes. For this analysis, baseline was defined as parent DRI12544 study baseline.

    Time frame: Baseline of parent study, Week 48 and Week 96 of this extension study

07

Results

Posted Nov 2, 2020

Participant flow

Study was initiated at 365 sites in 27 countries. Participants who successfully completed treatment in studies DRI12544 (NCT01854047),EFC13579 (NCT02414854),EFC13691 (NCT02528214) and PDY14192 (NCT02573233) were eligible to continue their treatment in this extension study LTS12551. Total of 2282 participants were enrolled and treated in this study.

Participant flow — Overall Study
MilestoneParticipants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/DupilumabParticipants From EFC13579: Placebo/DupilumabParticipants From EFC13579: Dupilumab/DupilumabParticipants From EFC13691: Placebo/DupilumabParticipants From EFC13691: Dupilumab/DupilumabParticipants From PDY14192: Placebo/DupilumabParticipants From PDY14192: Dupilumab/Dupilumab
Started111421517101397901914
Completed10237946590883761511
Not completed94252105141443
Withdrew: Lack of efficacy10321210
Withdrew: Poor compliance to protocol11371100
Withdrew: Other unspecified42233648621
Withdrew: Adverse event31913324512

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An Adverse Event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily had to have causal relationship with treatment. TEAEs were defined as AEs that developed, worsened, or became serious during the treatment emergent AE period (time from first dose of investigational medicinal product \[IMP\] in LTS12551 up to the last dose of dupilumab plus 14 weeks). A Serious AE (SAE) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.

Time frame:
From the first IMP injection in LTS12551 to the last IMP injection plus 14 weeks (up to 108 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsParticipants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/DupilumabParticipants From EFC13579: Placebo/DupilumabParticipants From EFC13579: Dupilumab/DupilumabParticipants From EFC13691: Placebo/DupilumabParticipants From EFC13691: Dupilumab/DupilumabParticipants From PDY14192: Placebo/DupilumabParticipants From PDY14192: Dupilumab/Dupilumab
Any TEAE8836941478974701813
Any treatment emergent SAE144248106121004
Any TEAE leading to death03010000
Any TEAE leading to permanent discontinuation31912314512
SecondaryNumber of Participants With Potentially Clinically Significant Vital Signs Abnormalities During the TEAE Period

Criteria for potentially clinically significant vital sign abnormalities: * Systolic blood pressure (SBP): Less than or equal to (≤) 95 Adults (≤90 Adolescents) millimeters of mercury (mmHg) and decrease from baseline (DFB) greater than or equal to (≥) 20 mmHg; ≥ 160 Adults (≥ 119 Adolescents) mmHg and increase from baseline (IFB) ≥ 20 mmHg. * Diastolic blood pressure (DBP): ≤ 45 Adults (≤54 Adolescents) mmHg and DFB ≥ 10 mmHg; ≥ 110 Adults (≥78 Adolescents) mmHg and IFB ≥ 10 mmHg. * Heart rate (HR): ≤ 50 beats per minute (bpm) and DFB ≥ 20 bpm; ≥ 120 bpm and IFB ≥ 20 bpm. * Respiratory rate: less than (\<) 12 breaths/min(b/m); greater than (\>) 20 b/m. * Weight (kg): ≥ 5 percent (%) DFB; ≥ 5% IFB. * Temperature: ≥ 38.0 degree Celsius (°C) rectal/ear/temporal; ≥ 37.5°C oral; ≥ 37.2°C axillary. TEAE period was defined as the time from first dose of IMP in LTS12551 up to the last dose of dupilumab plus 14 weeks.

Time frame:
From the first IMP injection in LTS12551 to the last IMP injection plus 14 weeks (up to 108 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities During the TEAE Period
ParticipantsParticipants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/DupilumabParticipants From EFC13579: Placebo/DupilumabParticipants From EFC13579: Dupilumab/DupilumabParticipants From EFC13691: Placebo/DupilumabParticipants From EFC13691: Dupilumab/DupilumabParticipants From PDY14192: Placebo/DupilumabParticipants From PDY14192: Dupilumab/Dupilumab
SBP: ≤ 95 (≤90) & DFB ≥ 20 mmHg41219400120
SBP: ≥ 160 (≥119) & IFB ≥ 20 mmHg21721456113
DBP: ≤ 45 (≤54) & DFB ≥ 10 mmHg1111150000
DBP: ≥ 110 (≥78) & IFB ≥ 10 mmHg0415202000
HR: ≤ 50 & DFB ≥ 20 bpm032120000
HR: ≥ 120 & IFB ≥ 20 bpm00251000
Respiratory rate: < 12 b/m51718244023
Respiratory rate: > 20 b/m2310488195181240
Weight: ≥ 5% DFB32106146261222933
Weight: ≥ 5% IFB45181189378293785
Temperature: ≥ 38.0°C00110000
Temperature: ≥ 37.5°C10960000
Temperature: ≥ 37.2°C3214160100
SecondaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters (Red Blood Cells [RBCs], Platelets and Coagulation) During the TEAE Period

Criteria for potentially clinically significant abnormalities: * Hemoglobin (Hb): ≤ 115 grams per liter (g/L)(Male \[M\]), ≤ 95 g/L (Female\[ F\]) (\< 100 g/L Adolescents); ≥ 185 g/L (M), ≥ 165 g/L (F) (≥ 200 g/L Adolescents); DFB ≥ 20 g/L. * Hematocrit: ≤ 0.37 volume/volume (v/v) (M); ≤ 0.32 v/v (F) (\<0.32 v/v Adolescents); ≥ 0.55 v/v (M); 0.5 v/v (F) (\>0.47 v/v Adolescents). * RBCs: ≥ 6 Tera/L. * Platelets: \< 100 Giga(G)/L; ≥ 700 G/L. TEAE period was defined as the time from first dose of IMP in LTS12551 up to the last dose of dupilumab plus 14 weeks.

Time frame:
From the first IMP injection in LTS12551 to the last IMP injection plus 14 weeks (up to 108 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters (Red Blood Cells [RBCs], Platelets and Coagulation) During the TEAE Period
ParticipantsParticipants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/DupilumabParticipants From EFC13579: Placebo/DupilumabParticipants From EFC13579: Dupilumab/DupilumabParticipants From EFC13691: Placebo/DupilumabParticipants From EFC13691: Dupilumab/DupilumabParticipants From PDY14192: Placebo/DupilumabParticipants From PDY14192: Dupilumab/Dupilumab
Hb: ≤ 115 g/L, ≤ 95 g/L (< 100 g/L)2712290300
Hb: ≥ 185 g/L, ≥ 165 g/L(≥ 200 g/L)13842100
Hb: DFB ≥ 20 g/L13414011811700
Hematocrit: ≤ 0.37 v/v; ≤ 0.32 v/v(<0.32 v/v)61923473500
Hematocrit: ≥ 0.55 v/v; ≥ 0.5 v/v(>0.47 v/v)3626363300
RBCs: ≥ 6 Tera/L158150201
Platelets: < 100G/ L02211001
Platelets: ≥ 700 G/L01100000
SecondaryNumber of Severe Exacerbation Events

Severe asthma exacerbation events were defined as a deterioration of asthma which required: use of systemic corticosteroids for ≥ 3 days, (participants from study EFC13691 (NCT02528214), and who were taking systemic corticosteroids: the use of systemic corticosteroids at least double the current dose and for ≥3 days.) or, hospitalization or emergency room visit because of asthma, required systemic corticosteroids.

Time frame:
From the first IMP injection in LTS12551 to the last IMP injection plus 2 weeks (up to 96 weeks)
Reported as:
Number · number of events
Number of Severe Exacerbation Events
number of eventsParticipants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/DupilumabParticipants From EFC13579: Placebo/DupilumabParticipants From EFC13579: Dupilumab/DupilumabParticipants From EFC13691: Placebo/DupilumabParticipants From EFC13691: Dupilumab/DupilumabParticipants From PDY14192: Placebo/DupilumabParticipants From PDY14192: Dupilumab/Dupilumab
Number of Severe Exacerbation Events62242234437354131
SecondaryAnnualized Event Rate Per Participant-Years for Severe Exacerbation

The annualized event rate per participant-years was defined as the total number of events that occurred during the treatment period divided by the total number of participant-years during the treatment period.

Time frame:
From the first IMP injection in LTS12551 to the last IMP injection plus 2 weeks (up to 96 weeks)
Reported as:
Number · exacerbation per participant-years
Annualized Event Rate Per Participant-Years for Severe Exacerbation
exacerbation per participant-yearsParticipants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/DupilumabParticipants From EFC13579: Placebo/DupilumabParticipants From EFC13579: Dupilumab/DupilumabParticipants From EFC13691: Placebo/DupilumabParticipants From EFC13691: Dupilumab/DupilumabParticipants From PDY14192: Placebo/DupilumabParticipants From PDY14192: Dupilumab/Dupilumab
Annualized Event Rate Per Participant-Years for Severe Exacerbation0.3140.3300.3510.3310.3020.3910.1490.077
SecondaryChange From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Weeks 48 and 96

FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. For this analysis, baseline was defined as respective parent study baseline.

Time frame:
Baseline of parent study, Week 48 and Week 96 of this extension study
Reported as:
Mean · liters
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Weeks 48 and 96
litersParticipants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/DupilumabParticipants From EFC13579: Placebo/DupilumabParticipants From EFC13579: Dupilumab/DupilumabParticipants From EFC13691: Placebo/DupilumabParticipants From EFC13691: Dupilumab/DupilumabParticipants From PDY14192: Placebo/DupilumabParticipants From PDY14192: Dupilumab/Dupilumab
Week 480.24 ± 0.420.28 ± 0.450.34 ± 0.440.36 ± 0.530.31 ± 0.500.33 ± 0.530.23 ± 0.400.01 ± 0.21
Week 960.22 ± 0.440.27 ± 0.460.33 ± 0.440.31 ± 0.470.36 ± 0.660.25 ± 0.460.14 ± 0.410.01 ± 0.12
SecondaryChange From Baseline in Percent Predicted FEV1 at Weeks 48 and 96

FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. For this analysis, baseline was defined as respective parent study baseline.

Time frame:
Baseline of parent study, Week 48 and Week 96 of this extension study
Reported as:
Mean · percent predicted FEV1
Change From Baseline in Percent Predicted FEV1 at Weeks 48 and 96
percent predicted FEV1Participants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/DupilumabParticipants From EFC13579: Placebo/DupilumabParticipants From EFC13579: Dupilumab/DupilumabParticipants From EFC13691: Placebo/DupilumabParticipants From EFC13691: Dupilumab/DupilumabParticipants From PDY14192: Placebo/DupilumabParticipants From PDY14192: Dupilumab/Dupilumab
Week 489.21 ± 13.6110.42 ± 14.6111.74 ± 14.2712.16 ± 16.5810.45 ± 15.0312.41 ± 18.275.88 ± 10.061.36 ± 8.35
Week 968.86 ± 14.4710.68 ± 15.1012.53 ± 14.5011.25 ± 14.5513.06 ± 19.5710.00 ± 15.794.20 ± 9.602.00 ± 2.83
SecondaryChange From Baseline in Forced Vital Capacity (FVC) at Weeks 48 and 96

FVC was a standard pulmonary function test used to quantify respiratory muscle weakness. FVC was the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. For this analysis, baseline was defined as respective parent study baseline.

Time frame:
Baseline of parent study, Week 48, and Week 96 of this extension study
Reported as:
Mean · liters
Change From Baseline in Forced Vital Capacity (FVC) at Weeks 48 and 96
litersParticipants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/DupilumabParticipants From EFC13579: Placebo/DupilumabParticipants From EFC13579: Dupilumab/DupilumabParticipants From EFC13691: Placebo/DupilumabParticipants From EFC13691: Dupilumab/DupilumabParticipants From PDY14192: Placebo/DupilumabParticipants From PDY14192: Dupilumab/Dupilumab
Week 480.22 ± 0.450.25 ± 0.500.30 ± 0.480.35 ± 0.600.29 ± 0.560.38 ± 0.560.21 ± 0.420.05 ± 0.30
Week 960.16 ± 0.470.22 ± 0.520.27 ± 0.480.25 ± 0.500.38 ± 0.820.22 ± 0.420.08 ± 0.290.05 ± 0.40
SecondaryChange From Baseline in Forced Expiratory Flow (FEF) 25-75% at Weeks 48 and 96

FEF was the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF 25-75% was defined as the mean FEF between 25% and 75% of the FVC, where FVC was defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. For this analysis, baseline was defined as respective parent study baseline.

Time frame:
Baseline of parent study, Week 48, and Week 96 of this extension study
Reported as:
Mean · liters/second
Change From Baseline in Forced Expiratory Flow (FEF) 25-75% at Weeks 48 and 96
liters/secondParticipants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/DupilumabParticipants From EFC13579: Placebo/DupilumabParticipants From EFC13579: Dupilumab/DupilumabParticipants From EFC13691: Placebo/DupilumabParticipants From EFC13691: Dupilumab/DupilumabParticipants From PDY14192: Placebo/DupilumabParticipants From PDY14192: Dupilumab/Dupilumab
Week 480.27 ± 0.550.31 ± 0.550.39 ± 0.570.39 ± 0.660.34 ± 0.560.29 ± 0.660.23 ± 0.440.04 ± 0.26
Week 960.28 ± 0.570.32 ± 0.550.38 ± 0.530.36 ± 0.610.42 ± 0.640.27 ± 0.530.19 ± 0.410.04 ± 0.14
SecondaryChange From Baseline in Asthma Control Questionnaire 5-Question Version (ACQ-5) Mean Scores at Weeks 24 and 48

The ACQ-5 had 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total mean score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), higher scores indicated lower asthma control. For this analysis, baseline was defined as respective parent study baseline.

Time frame:
Baseline of parent study, Weeks 24, and 48 of this extension study
Reported as:
Mean · score on a scale
Change From Baseline in Asthma Control Questionnaire 5-Question Version (ACQ-5) Mean Scores at Weeks 24 and 48
score on a scaleParticipants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/DupilumabParticipants From EFC13579: Placebo/DupilumabParticipants From EFC13579: Dupilumab/DupilumabParticipants From EFC13691: Placebo/DupilumabParticipants From EFC13691: Dupilumab/DupilumabParticipants From PDY14192: Placebo/DupilumabParticipants From PDY14192: Dupilumab/Dupilumab
Week 24-1.37 ± 0.91-1.48 ± 1.10-1.61 ± 1.08-1.68 ± 1.05-1.09 ± 1.10-1.15 ± 1.17-0.96 ± 1.03-0.80 ± 0.46
Week 48-1.33 ± 1.07-1.57 ± 1.11-1.64 ± 1.08-1.69 ± 1.08-1.21 ± 1.00-1.06 ± 1.25-0.89 ± 1.02-0.87 ± 0.58
SecondaryPercentage of Participants Achieving ACQ-5 Score Response (ACQ-5 Responders) at Weeks 24 and 48

ACQ-5 response was defined as change from baseline in ACQ-5 scores ≥ 0.5. The ACQ-5 had 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 mean total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.

Time frame:
At Weeks 24, and 48 of this extension study
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ACQ-5 Score Response (ACQ-5 Responders) at Weeks 24 and 48
percentage of participantsParticipants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/DupilumabParticipants From EFC13579: Placebo/DupilumabParticipants From EFC13579: Dupilumab/DupilumabParticipants From EFC13691: Placebo/DupilumabParticipants From EFC13691: Dupilumab/DupilumabParticipants From PDY14192: Placebo/DupilumabParticipants From PDY14192: Dupilumab/Dupilumab
Week 2482.780.884.086.567.770.157.969.2
Week 4879.082.385.786.775.670.560.072.7
SecondaryChange From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Global Scores at Weeks 24 and 48

The AQLQ was designed to measure the functional impairments that are most troublesome to adults as a result of their asthma. The AQLQ comprised of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), and environmental stimuli (4 items). Each item was scored on a 7-point likert scale ranged from 1=severely impaired to 7=not impaired. The 32 items of the questionnaire were averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired); higher scores indicated better quality of life. For this analysis, baseline was defined as respective parent study baseline.

Time frame:
Baseline of parent study, Weeks 24, and 48 of this extension study
Reported as:
Mean · score on a scale
Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Global Scores at Weeks 24 and 48
score on a scaleParticipants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/DupilumabParticipants From EFC13579: Placebo/DupilumabParticipants From EFC13579: Dupilumab/DupilumabParticipants From EFC13691: Placebo/DupilumabParticipants From EFC13691: Dupilumab/Dupilumab
Week 241.07 ± 0.991.28 ± 1.241.38 ± 1.151.38 ± 1.160.99 ± 1.100.97 ± 1.26
Week 481.07 ± 1.131.40 ± 1.191.39 ± 1.171.40 ± 1.181.06 ± 0.981.00 ± 1.23
SecondaryPercentage of Participants Achieving AQLQ Global Score Response (AQLQ Responders) at Weeks 24 and 48

AQLQ global response was defined as participants with change from baseline in AQLQ global score ≥ 0.5. The AQLQ was designed to measure the functional impairments that are most troublesome to adults as a result of their asthma. The AQLQ comprised of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item was scored on a 7-point likert scale (1=severely impaired, 7=not impaired). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired). Higher scores indicated better quality of life.

Time frame:
At Weeks 24, and 48 of this extension study
Reported as:
Number · percentage of participants
Percentage of Participants Achieving AQLQ Global Score Response (AQLQ Responders) at Weeks 24 and 48
percentage of participantsParticipants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/DupilumabParticipants From EFC13579: Placebo/DupilumabParticipants From EFC13579: Dupilumab/DupilumabParticipants From EFC13691: Placebo/DupilumabParticipants From EFC13691: Dupilumab/Dupilumab
Week 2467.673.677.677.264.261.4
Week 4865.076.377.478.473.368.4
SecondarySerum Concentrations of Dupilumab Over Time Till Week 96

For this analysis, baseline was defined as respective parent study baseline. Here, 'number analyzed'=number of participants with available data for each specified category.

Time frame:
Baseline of parent study, Weeks 0, 4, 12, 24, 48, 72, and 96 of this extension study
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Serum Concentrations of Dupilumab Over Time Till Week 96
nanogram per milliliter (ng/mL)Participants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/DupilumabParticipants From EFC13579: Placebo/DupilumabParticipants From EFC13579: Dupilumab/DupilumabParticipants From EFC13691: Placebo/DupilumabParticipants From EFC13691: Dupilumab/DupilumabParticipants From PDY14192: Placebo/DupilumabParticipants From PDY14192: Dupilumab/Dupilumab
Baseline0.00 ± 0.0000.00 ± 1990.640—0.00 ± 2286.888—0.00 ± 0.000—0.00 ± 0.000
Week 00.00 ± 0.0000.00 ± 0.000—37230.97 ± 73.261—40754.49 ± 54.858—52545.41 ± 44.678
Week 446848.70 ± 43.14940704.77 ± 47.29325847.86 ± 49.37150566.66 ± 55.10425868.25 ± 53.45048295.93 ± 52.65523336.89 ± 50.54256486.58 ± 45.755
Week 1254467.13 ± 50.26748155.26 ± 52.35345406.55 ± 51.39955140.49 ± 53.11444064.95 ± 57.10050904.34 ± 51.23349026.51 ± 41.61955365.35 ± 53.317
Week 2447023.84 ± 51.64549730.56 ± 53.62550984.57 ± 53.74454897.58 ± 54.04457363.72 ± 57.88944219.42 ± 55.38363080.82 ± 51.22460643.16 ± 41.617
Week 4846355.26 ± 52.61245919.75 ± 55.93241867.50 ± 60.34541849.96 ± 62.04936219.47 ± 67.53036564.41 ± 60.95924864.79 ± 58.01653320.11 ± 46.714
Week 7244771.52 ± 56.25646842.64 ± 53.33545628.10 ± 56.23246372.55 ± 57.71960117.76 ± 62.39032029.19 ± 66.78540362.88 ± 55.56726383.90 ± 120.013
Week 9642431.08 ± 59.22242661.18 ± 59.65838908.58 ± 64.63339088.60 ± 62.89749810.65 ± 65.54619030.70 ± 67.23742360.37 ± 49.40956378.01 ± 7.140
SecondaryPercentage of Participants With Antidrug Antibodies (ADA) Response

ADA response were categorized as: treatment emergent and treatment boosted response. 1) Treatment emergent was defined as an ADA positive response in the assay post first dose in LTS12551, when baseline results were negative or missing. 2) Treatment boosted was defined as: an ADA positive response in the assay post first dose that was greater-than or equal to 4-fold over baseline titer levels, when baseline results were positive. The criteria for positive was defined as "30 to \> 10,000", where low titer (\< 1,000); moderate (1,000 ≤ titer ≤ 10,000) and high titer (\> 10,000).

Time frame:
From the first IMP injection in LTS12551 to the last IMP injection plus 2 weeks (up to 96 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Antidrug Antibodies (ADA) Response
percentage of participantsParticipants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/DupilumabParticipants From EFC13579: Placebo/DupilumabParticipants From EFC13579: Dupilumab/DupilumabParticipants From EFC13691: Placebo/DupilumabParticipants From EFC13691: Dupilumab/DupilumabParticipants From PDY14192: Placebo/DupilumabParticipants From PDY14192: Dupilumab/Dupilumab
Treatment-emergent ADA10.812.19.54.57.48.907.1
Treatment-boosted ADA00001.1000
SecondaryChange From Baseline in Blood Eosinophils Cells Count at Weeks 48 and 96

For this analysis, baseline was defined as respective parent study baseline.

Time frame:
Baseline of parent study, Week 48 and Week 96 of this extension study
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Blood Eosinophils Cells Count at Weeks 48 and 96
10^9 cells/LParticipants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/DupilumabParticipants From EFC13579: Placebo/DupilumabParticipants From EFC13579: Dupilumab/DupilumabParticipants From EFC13691: Placebo/DupilumabParticipants From EFC13691: Dupilumab/DupilumabParticipants From PDY14192: Placebo/DupilumabParticipants From PDY14192: Dupilumab/Dupilumab
Week 480.007 ± 0.475-0.041 ± 0.588-0.096 ± 0.428-0.099 ± 0.3600.098 ± 0.4500.016 ± 0.382-0.066 ± 0.181-0.026 ± 0.187
Week 96-0.074 ± 0.251-0.081 ± 0.562-0.161 ± 0.391-0.114 ± 0.354-0.051 ± 0.3990.083 ± 0.642-0.103 ± 0.0390.025 ± 0.134
SecondaryChange From Baseline in Morning Peak Expiratory Flow (PEF) at Weeks 48 and 96: Participants From Study DRI12544

The PEF was a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at morning and evening. Morning PEF was performed within 15 minutes after arising (between 5:30 AM and 10 AM) prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol. For this analysis, baseline was defined as parent study DRI12544 baseline.

Time frame:
Baseline of parent study, Week 48 and Week 96 of this extension study
Reported as:
Mean · liters per minute (L/min)
Change From Baseline in Morning Peak Expiratory Flow (PEF) at Weeks 48 and 96: Participants From Study DRI12544
liters per minute (L/min)Participants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/Dupilumab
Week 4813.26 ± 76.7122.95 ± 70.06
Week 9613.63 ± 83.8821.69 ± 77.70
SecondaryChange From Baseline in Evening Peak Expiratory Flow (PEF) at Weeks 48 and 96: Participants From Study DRI12544

The PEF was a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at morning and evening. Evening PEF was performed in the evening (between 5:30 PM and 10 PM) prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol. For this analysis, baseline was defined as parent DRI12544 study baseline.

Time frame:
Baseline of parent study, Week 48 and Week 96 of this extension study
Reported as:
Mean · L/min
Change From Baseline in Evening Peak Expiratory Flow (PEF) at Weeks 48 and 96: Participants From Study DRI12544
L/minParticipants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/Dupilumab
Week 484.65 ± 75.0011.97 ± 72.19
Week 961.16 ± 79.4710.05 ± 79.47
SecondaryChange From Baseline in Morning Asthma Symptom Scores at Weeks 48 and 96: Participants From Study DRI12544

Morning asthma symptom score was determined using AM (ante meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the night. It ranges from 0 to 4 as: 0=no asthma symptoms, slept through the night, 1=slept well, but some complaints in the morning. No nighttime awakenings, 2=woke up once because of asthma (including early awakening), 3=woke up several times because of asthma (including early awakening), 4=bad night, awake most of the night because of asthma; higher scores indicated more severe symptoms. For this analysis, baseline was defined as parent DRI12544 study baseline.

Time frame:
Baseline of parent study, Week 48 and Week 96 of this extension study
Reported as:
Mean · score on a scale
Change From Baseline in Morning Asthma Symptom Scores at Weeks 48 and 96: Participants From Study DRI12544
score on a scaleParticipants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/Dupilumab
Week 48-0.49 ± 0.78-0.68 ± 0.79
Week 96-0.52 ± 0.90-0.76 ± 0.81
SecondaryChange From Baseline in Evening Asthma Symptom Scores at Weeks 48 and 96: Participants From Study DRI12544

Evening asthma symptom score was determined using PM (post meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual; higher scores indicated more severe symptoms. For this analysis, baseline was defined as parent DRI12544 study baseline.

Time frame:
Baseline of parent study, Week 48, and Week 96 of this extension study
Reported as:
Mean · score on a scale
Change From Baseline in Evening Asthma Symptom Scores at Weeks 48 and 96: Participants From Study DRI12544
score on a scaleParticipants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/Dupilumab
Week 48-0.47 ± 0.81-0.72 ± 0.85
Week 96-0.49 ± 0.94-0.79 ± 0.88
SecondaryChange From Baseline in Number of Inhalations Per Day of Salbutamol/Albuterol or Levosalbutamol/Levalbuterol for Symptom Relief at Weeks 48 and 96: Participants From Study DRI12544

The number of salbutamol/albuterol or levosalbutamol/levalbuterol inhalations was recorded daily by the participants in an electronic diary/PEF meter. Mean number of inhalations in last 7 days prior to each visit was calculated and was used in computation of data reported. For this analysis, baseline was defined as parent DRI12544 study baseline.

Time frame:
Baseline of parent study, Week 48, and Week 96 of this extension study
Reported as:
Mean · inhalations per day
Change From Baseline in Number of Inhalations Per Day of Salbutamol/Albuterol or Levosalbutamol/Levalbuterol for Symptom Relief at Weeks 48 and 96: Participants From Study DRI12544
inhalations per dayParticipants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/Dupilumab
Week 48-0.00 ± 3.650.68 ± 4.80
Week 96-0.14 ± 4.17-0.82 ± 5.18
SecondaryChange From Baseline in Number of Nocturnal Awakenings at Weeks 48 and 96: Participants From Study DRI12544

The number of nocturnal awakening because of asthma symptoms were recorded every morning by the participants in an electronic diary. Mean number of awakenings in last 7 days prior to each visit was calculated and was used in computation of data reported. For this analysis, baseline was defined as parent DRI12544 study baseline.

Time frame:
Baseline of parent study, Week 48 and Week 96 of this extension study
Reported as:
Mean · nocturnal awakenings
Change From Baseline in Number of Nocturnal Awakenings at Weeks 48 and 96: Participants From Study DRI12544
nocturnal awakeningsParticipants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/Dupilumab
Week 48-0.27 ± 0.54-0.43 ± 0.89
Week 96-0.29 ± 0.58-0.49 ± 0.96
SecondaryPercent Change From Baseline in Oral Corticosteroid (OCS) Dose at Weeks 48, and 96: Participants From Study EFC13691

OCS was allowed as background controller medication for the participants from study EFC13691 only. For this analysis, baseline was defined as parent study EFC13691 baseline.

Time frame:
Baseline of parent study, Weeks 48 and 96 of this extension study
Reported as:
Mean · percent change
Percent Change From Baseline in Oral Corticosteroid (OCS) Dose at Weeks 48, and 96: Participants From Study EFC13691
percent changeParticipants From EFC13691: Placebo/DupilumabParticipants From EFC13691: Dupilumab/Dupilumab
Week 4855.32 ± 42.9880.23 ± 30.44
Week 9671.37 ± 29.3788.16 ± 26.83
SecondaryPercentage of Participants Achieving a Reduction of 50% or Greater (≥ 50% ) in OCS Dose Over Time at Weeks 48 and 96: Participants From Study EFC13691

OCS was allowed as background controller medication for the participants from study EFC13691 only. Percentage of participants who achieved a reduction of ≥ 50% in OCS dose were reported.

Time frame:
Weeks 48 and 96 of this extension study
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Reduction of 50% or Greater (≥ 50% ) in OCS Dose Over Time at Weeks 48 and 96: Participants From Study EFC13691
percentage of participantsParticipants From EFC13691: Placebo/DupilumabParticipants From EFC13691: Dupilumab/Dupilumab
Week 4864.986.0
Week 9682.194.7
SecondaryPercentage of Participants With Background OCS Completely Tapered Off Over Time at Weeks 48 and 96: Participants From Study EFC13691

OCS was allowed as background controller medication for the participants from study EFC13691 only. Number of participants who gradually discontinued or reduced therapeutic dose were reported in this outcome measure.

Time frame:
Weeks 48, and 96 of this extension study
Reported as:
Number · percentage of participants
Percentage of Participants With Background OCS Completely Tapered Off Over Time at Weeks 48 and 96: Participants From Study EFC13691
percentage of participantsParticipants From EFC13691: Placebo/DupilumabParticipants From EFC13691: Dupilumab/Dupilumab
Week 4831.259.6
Week 9642.978.9
SecondaryChange From Baseline in European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Scores at Weeks 48 and 96: Participants From Study DRI12544

EQ-5D-3L: validated and reliable self-report health status questionnaire consisted of EQ-5D descriptive system and visual analogue scale (VAS). EQ-5D descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension measured on 3 levels: no problem, some problems, and severe problems. The 5 dimensional 3-level systems was converted into single index utility score, and the score was 0 - 100, where 100=best health state; and 0=worst health state; where higher scores indicated better outcome. For this analysis, baseline was defined as parent DRI12544 study baseline.

Time frame:
Baseline of parent study, Week 48 and Week 96 of this extension study
Reported as:
Mean · score on a scale
Change From Baseline in European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Scores at Weeks 48 and 96: Participants From Study DRI12544
score on a scaleParticipants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/Dupilumab
Week 480.13 ± 0.200.14 ± 0.21
Week 960.12 ± 0.180.13 ± 0.21
SecondaryChange From Baseline in EQ-5D-3L VAS Scores at Weeks 48 and 96: Participants From Study DRI12544

EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0=worst imaginable health state and 100=best imaginable health state, where higher states indicated better outcomes. For this analysis, baseline was defined as parent DRI12544 study baseline.

Time frame:
Baseline of parent study, Week 48 and Week 96 of this extension study
Reported as:
Mean · score on a scale
Change From Baseline in EQ-5D-3L VAS Scores at Weeks 48 and 96: Participants From Study DRI12544
score on a scaleParticipants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/Dupilumab
Week 4810.10 ± 15.4012.88 ± 18.76
Week 969.90 ± 18.9213.95 ± 18.81

Adverse events

Collected over Reported AE and deaths were TEAEs that developed, worsened, or became serious and deaths that occurred during the TEAE period (time from the first dose of dupilumab in LTS12551 up to the last dose of dupilumab plus 14 weeks) (i.e. up to 108 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants From DRI12544 Study Placebo/Dupilumab0/111 (0%)14/111 (12.6%)80/111 (72.1%)
Participants From DRI12544 Study Dupilumab/Dupilumab3/421 (0.7%)42/421 (10%)323/421 (76.7%)
Participants From EFC13579 Study Placebo/Dupilumab0/517 (0%)48/517 (9.3%)357/517 (69.1%)
Participants From EFC13579 Study Dupilumab/Dupilumab1/1,013 (0.1%)106/1,013 (10.5%)666/1,013 (65.7%)
Participants From EFC13691 Study Placebo/Dupilumab0/97 (0%)12/97 (12.4%)56/97 (57.7%)
Participants From EFC13691 Study Dupilumab/Dupilumab0/90 (0%)10/90 (11.1%)55/90 (61.1%)
Participants From PDY14192 Study Placebo/Dupilumab0/19 (0%)0/19 (0%)18/19 (94.7%)
Participants From PDY14192 Study Dupilumab/Dupilumab0/14 (0%)4/14 (28.6%)13/14 (92.9%)
Most frequent serious events
Showing 10 of 178
Most frequent serious events
EventParticipants From DRI12544 Study Placebo/DupilumabParticipants From DRI12544 Study Dupilumab/DupilumabParticipants From EFC13579 Study Placebo/DupilumabParticipants From EFC13579 Study Dupilumab/DupilumabParticipants From EFC13691 Study Placebo/DupilumabParticipants From EFC13691 Study Dupilumab/DupilumabParticipants From PDY14192 Study Placebo/DupilumabParticipants From PDY14192 Study Dupilumab/Dupilumab
Diaphragmatic HerniaGastrointestinal disorders0/1110/4210/5170/10130/970/900/191/14
Squamous Cell Carcinoma Of SkinNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1110/4210/5170/10130/970/900/191/14
Abortion SpontaneousPregnancy, puerperium and perinatal conditions0/1112/4210/5170/10130/970/900/191/14
AsthmaRespiratory, thoracic and mediastinal disorders4/1112/42113/51718/10130/975/900/191/14
PneumoniaInfections and infestations3/1114/4214/5177/10131/971/900/190/14
Acute Coronary SyndromeCardiac disorders0/1110/4210/5170/10130/971/900/190/14
Eosinophilic Granulomatosis With PolyangiitisImmune system disorders0/1110/4210/5172/10131/971/900/190/14
Fibroadenoma Of BreastNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1110/4210/5171/10130/971/900/190/14
NeuritisNervous system disorders0/1110/4210/5170/10130/971/900/190/14
SyncopeNervous system disorders0/1111/4210/5171/10130/971/900/190/14
Most frequent other events
Showing 10 of 116
Most frequent other events
EventParticipants From DRI12544 Study Placebo/DupilumabParticipants From DRI12544 Study Dupilumab/DupilumabParticipants From EFC13579 Study Placebo/DupilumabParticipants From EFC13579 Study Dupilumab/DupilumabParticipants From EFC13691 Study Placebo/DupilumabParticipants From EFC13691 Study Dupilumab/DupilumabParticipants From PDY14192 Study Placebo/DupilumabParticipants From PDY14192 Study Dupilumab/Dupilumab
Injection Site ErythemaGeneral disorders26/11155/42135/51750/10135/972/908/196/14
NasopharyngitisInfections and infestations27/111109/42199/517191/101317/9716/903/196/14
ContusionInjury, poisoning and procedural complications3/11114/42112/51714/10130/972/900/193/14
Back PainMusculoskeletal and connective tissue disorders4/11130/42123/51752/10135/970/902/193/14
VomitingGastrointestinal disorders2/1114/4215/51713/10130/970/904/190/14
HeadacheNervous system disorders13/11147/42147/51774/10134/975/904/191/14
BronchitisInfections and infestations15/11180/42163/517117/10139/9714/900/190/14
Upper Respiratory Tract InfectionInfections and infestations18/11160/42165/517130/10138/976/902/190/14
NauseaGastrointestinal disorders2/1116/4218/51714/10130/970/903/191/14
Injection Site OedemaGeneral disorders4/11114/42114/51715/10130/972/903/192/14

Baseline characteristics

Analysis was performed on all enrolled participants.

Age, Customized
Age, Customized(Participants)Participants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/DupilumabParticipants From EFC13579: Placebo/DupilumabParticipants From EFC13579: Dupilumab/DupilumabParticipants From EFC13691: Placebo/DupilumabParticipants From EFC13691: Dupilumab/DupilumabParticipants From PDY14192: Placebo/DupilumabParticipants From PDY14192: Dupilumab/DupilumabTotal
<18 years003255110089
18-64 years101374422826818019141917
65-74 years8405911214800241
75-84 years27420110035
≥85 years000000000
Sex: Female, Male
Sex: Female, Male(Participants)Participants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/DupilumabParticipants From EFC13579: Placebo/DupilumabParticipants From EFC13579: Dupilumab/DupilumabParticipants From EFC13691: Placebo/DupilumabParticipants From EFC13691: Dupilumab/DupilumabParticipants From PDY14192: Placebo/DupilumabParticipants From PDY14192: Dupilumab/DupilumabTotal
Female6925933561857537101408
Male421621823954037124874
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Participants From DRI12544: Placebo/DupilumabParticipants From DRI12544: Dupilumab/DupilumabParticipants From EFC13579: Placebo/DupilumabParticipants From EFC13579: Dupilumab/DupilumabParticipants From EFC13691: Placebo/DupilumabParticipants From EFC13691: Dupilumab/DupilumabParticipants From PDY14192: Placebo/DupilumabParticipants From PDY14192: Dupilumab/DupilumabTotal
American Indian or Alaska Native000020002
Asian1870511161001257
Native Hawaiian or Other Pacific Islander010101003
Black or African American181743122175
White88339445844918617121922
More than one race000000000
Unknown or Not Reported4349210023
08

Study locations

365 sites
  • Investigational Site Number 840047
    Birmingham, Alabama 35209, United States
  • Investigational Site Number 840099
    Gilbert, Arizona 85234, United States
  • Investigational Site Number 840087
    Scottsdale, Arizona 85251, United States
  • Investigational Site Number 840402
    Tucson, Arizona 85724, United States
  • Investigational Site Number 840132
    Little Rock, Arkansas 72209, United States
  • Investigational Site Number 840109
    Bakersfield, California 93301, United States
  • Investigational Site Number 840045
    Long Beach, California 90720, United States
  • Investigational Site Number 840019
    Los Angeles, California 90025, United States
  • Investigational Site Number 840029
    Los Angeles, California 90025, United States
  • Investigational Site Number 840022
    Los Angeles, California 90048, United States
  • Investigational Site Number 840044
    Newport Beach, California 92663, United States
  • Investigational Site Number 840041
    North Hollywood, California 91606, United States
  • Investigational Site Number 840014
    Rolling Hills Estates, California 90274, United States
  • Investigational Site Number 840121
    San Jose, California 95117, United States
  • Investigational Site Number 840040
    Colorado Springs, Colorado 80907, United States
  • Investigational Site Number 840403
    Denver, Colorado 80206, United States
  • Investigational Site Number 840006
    Denver, Colorado 80230, United States
  • Investigational Site Number 840024
    Denver, Colorado 80230, United States
  • Investigational Site Number 840130
    Denver, Colorado 80246, United States
  • Investigational Site Number 840902
    New Haven, Connecticut 06510, United States
  • Investigational Site Number 840137
    Aventura, Florida 33180, United States
  • Investigational Site Number 840071
    Gainesville, Florida 32607, United States
  • Investigational Site Number 840115
    Ocoee, Florida 34761, United States
  • Investigational Site Number 840055
    Sarasota, Florida 34239, United States
  • Investigational Site Number 840079
    Twin Falls, Idaho 83301, United States
  • Investigational Site Number 840101
    Chicago, Illinois 60611, United States
  • Investigational Site Number 840032
    Fort Mitchell, Kentucky 41017, United States
  • Investigational Site Number 840017
    Louisville, Kentucky 40223-5440, United States
  • Investigational Site Number 840030
    Owensboro, Kentucky 42301, United States
  • Investigational Site Number 840064
    Bangor, Maine 04401, United States
  • Investigational Site Number 840052
    Chevy Chase, Maryland 20815, United States
  • Investigational Site Number 840073
    Gaithersburg, Maryland 20878, United States
  • Investigational Site Number 840080
    Owings Mills, Maryland 21117, United States
  • Investigational Site Number 840401
    Boston, Massachusetts 02115, United States
  • Investigational Site Number 840018
    Minneapolis, Minnesota 55402, United States
  • Investigational Site Number 840002
    Saint Louis, Missouri 63110, United States
  • Investigational Site Number 840102
    Saint Louis, Missouri 63141, United States
  • Investigational Site Number 840093
    Saint Louis, Missouri, United States
  • Investigational Site Number 840037
    Missoula, Montana 59808, United States
  • Investigational Site Number 840078
    Omaha, Nebraska 68124, United States
  • Investigational Site Number 840004
    Papillion, Nebraska 27103, United States
  • Investigational Site Number 840111
    Brick, New Jersey 08723, United States
  • Investigational Site Number 840068
    Ocean City, New Jersey 07712, United States
  • Investigational Site Number 840011
    Princeton, New Jersey 08540, United States
  • Investigational Site Number 840065
    New York, New York 10029, United States
  • Investigational Site Number 840126
    Charlotte, North Carolina 28226, United States
  • Investigational Site Number 840083
    Charlotte, North Carolina 28277, United States
  • Investigational Site Number 840108
    Durham, North Carolina 27705, United States
  • Investigational Site Number 840107
    Greensboro, North Carolina 27401, United States
  • Investigational Site Number 840907
    High Point, North Carolina 27262, United States
  • Investigational Site Number 840404
    Winston-Salem, North Carolina 27157-1071, United States
  • Investigational Site Number 840015
    Cincinnati, Ohio 45236, United States
  • Investigational Site Number 840146
    Cincinnati, Ohio 45241, United States
  • Investigational Site Number 840049
    Middleburg Heights, Ohio 44130, United States
  • Investigational Site Number 840942
    Toledo, Ohio 43617, United States
  • Investigational Site Number 840112
    Edmond, Oklahoma 73034, United States
  • Investigational Site Number 840104
    Tulsa, Oklahoma 74136, United States
  • Investigational Site Number 840034
    Medford, Oregon 97504, United States
  • Investigational Site Number 840031
    Portland, Oregon 97223, United States
  • Investigational Site Number 840046
    Bethlehem, Pennsylvania 18020, United States
  • Investigational Site Number 840085
    Hershey, Pennsylvania 17033, United States
  • Investigational Site Number 840067
    Philadelphia, Pennsylvania 19140, United States
  • Investigational Site Number 840928
    Pittsburgh, Pennsylvania 15213, United States
  • Investigational Site Number 840091
    Pittsburgh, Pennsylvania 15241, United States
  • Investigational Site Number 840082
    Charleston, South Carolina 29407, United States
  • Investigational Site Number 840117
    Greenville, South Carolina 29607, United States
  • Investigational Site Number 840021
    Spartanburg, South Carolina 29303, United States
  • Investigational Site Number 840062
    Amarillo, Texas 79106, United States
  • Investigational Site Number 840038
    Boerne, Texas 78006, United States
  • Investigational Site Number 840124
    Cypress, Texas 77429, United States
  • Investigational Site Number 840023
    Dallas, Texas 75231, United States
  • Investigational Site Number 840923
    El Paso, Texas 79903, United States
  • Investigational Site Number 840922
    Fort Worth, Texas 76109, United States
  • Investigational Site Number 840027
    Fort Worth, Texas 76244, United States
  • Investigational Site Number 840070
    McKinney, Texas 75069, United States
  • Investigational Site Number 840118
    Plano, Texas 75093, United States
  • Investigational Site Number 840008
    San Antonio, Texas 78229, United States
  • Investigational Site Number 840035
    Draper, Utah 84020, United States
  • Investigational Site Number 840077
    Murray, Utah 84107, United States
  • Investigational Site Number 840057
    South Burlington, Vermont 05403, United States
  • Investigational Site Number 840059
    Fairfax, Virginia 22030, United States
  • Investigational Site Number 840951
    Bellingham, Washington 98225, United States
  • Investigational Site Number 032096
    Bahia Blanca, B8000JRB, Argentina
  • Investigational Site Number 032004
    Buenos Aires, B6500BWQ, Argentina
  • Investigational Site Number 032003
    Buenos Aires, C1121ABE, Argentina
  • Investigational Site Number 032011
    Caba, 1120, Argentina
  • Investigational Site Number 032097
    Caba, C1414AIF, Argentina
  • Investigational Site Number 032001
    Caba, C1425BEN, Argentina
  • Investigational Site Number 032010
    Caba, C1425FVH, Argentina
  • Investigational Site Number 032091
    Caba, C1426ABP, Argentina
  • Investigational Site Number 032095
    Capital Federal, C1425DUC, Argentina
  • Investigational Site Number 032002
    La Plata, B1900BNN, Argentina
  • Investigational Site Number 032006
    Rosario, S2000BRH, Argentina
  • Investigational Site Number 032007
    Rosario, S2000DBS, Argentina
  • Investigational Site Number 032005
    Rosario, S2000JKR, Argentina
  • Investigational Site Number 032012
    San Miguel De Tucuman, T4000CHE, Argentina
  • Investigational Site Number 032009
    San Miguel De Tucumán, T4000IAR, Argentina
  • Investigational Site Number 036004
    Adelaide, 5000, Australia
  • Investigational Site Number 036005
    Campbelltown, 2560, Australia
  • Investigational Site Number 036001
    Clayton, 3168, Australia

Showing the first 100 of 365 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Tohda Y, Nakamura Y, Fujisawa T, Ebisawa M, Msihid J, Djandji M, Ortiz B, Jacob-Nara JA, Deniz Y, Rowe PJ, Ishida M, Arima K. Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma recruited from Japanese centers in the phase 3 LIBERTY ASTHMA TRAVERSE study. Allergol Int. 2023 Jan;72(1):89-99. doi: 10.1016/j.alit.2022.07.008. Epub 2022 Sep 13. PubMed 36114102 ↗
  • Lugogo N, Mohan A. Are We Poised to Change the Trajectory of Maintenance Oral Corticosteroid Use in Severe Asthma in the Age of Biologics? Chest. 2022 Jul;162(1):4-5. doi: 10.1016/j.chest.2022.04.004. No abstract available. PubMed 35809937 ↗
  • Wechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan A, Johnson RR, Kapoor U, Khokhar FA, Daizadeh N, Chen Z, Laws E, Ortiz B, Jacob-Nara JA, Mannent LP, Rowe PJ, Deniz Y. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis. J Allergy Clin Immunol Pract. 2022 Oct;10(10):2695-2709. doi: 10.1016/j.jaip.2022.05.019. Epub 2022 May 28. PubMed 35636689 ↗
  • Sher LD, Wechsler ME, Rabe KF, Maspero JF, Daizadeh N, Mao X, Ortiz B, Mannent LP, Laws E, Ruddy M, Pandit-Abid N, Jacob-Nara JA, Gall R, Rowe PJ, Deniz Y, Lederer DJ, Hardin M. Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial. Chest. 2022 Jul;162(1):46-55. doi: 10.1016/j.chest.2022.01.071. Epub 2022 Feb 22. PubMed 35217003 ↗
  • Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A, Watz H, Castro M, Nenasheva NM, Tohda Y, Langton D, Cardona G, Domingo C, Park HS, Chapman KR, Mao X, Zhang Y, Khan AH, Deniz Y, Rowe PJ, Kapoor U, Khokhar FA, Mannent LP, Ruddy M, Laws E, Amin N, Hardin M. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022 Jan;10(1):11-25. doi: 10.1016/S2213-2600(21)00322-2. Epub 2021 Sep 28. PubMed 34597534 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2014 to primary completion in Oct 2019, 62 months.

Results were first posted in Nov 2020, 1 year after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 62 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2014
First posted
May 8, 2014
StartActual
Aug 5, 2014
Primary completionActual
Oct 11, 2019
CompletionActual
Oct 11, 2019
Results first posted
Nov 2, 2020
Last update
Mar 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02134028
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 8, 2014
Start date
Aug 5, 2014
Primary completion
Oct 11, 2019
Completion
Oct 11, 2019
Results posted
Nov 2, 2020
Last update
Mar 28, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion